Eurofins Scientific Se · EURONEXT:ERF
Eurofins Scientific — Q1 2024 Earnings Presentation
10 slides from Eurofins Scientific's earnings presentation, Apr 24, 2024
Slide 1: Q1 2024 Trading Update
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2024. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Key financial and operational highlights
Key financial and operational highlights Reported Revenues Key Highlights • Increase of 5.0% in reported revenues vs Q1 2023 driven by organic growth but slightly restrained by FX (-1.0%). The period also comprised nearly one less public working day, an effect that will mostly reverse in Q2 2024. €1
Slide 4: Breakdown of Revenue by Operating Segment
Breakdown of Revenue by Operating Segment Organic growth in the Core Organic growth €m Q1 2024 As % of total Q1 2023 As % of total Y-o-Y in the Core Business* variation % adjusted for Business * public working days Europe 850 51.4% 797 50.6% 6.6% 4.1% 6.1% North America 628 38.0% 607 38.5% 3.5% ** 7
Slide 5: Revenue bridge
Revenue bridge (€m) 1,653 Q1 2024: zero Q1 2023: just below €10m • FX headwind (-1.0%) due to the strength of the Euro against the US Dollar and 1,586 numerous Asian currencies 1,574 • Adjusted for one less public working day in Q1 2024, organic revenue growth in the Core Business (excluding COVID-1
Slide 6: 2024 and 2027 Objectives confirmed
2024 and 2027 Objectives confirmed (€m) FY 2024 Mid-term objectives FY 2027 +6.5% organic growth p.a. Revenues €7.075bn – €7.175bn €250m revenues added from M&A p.a. Approaching €10bn Adj. EBITDA €1.525bn – €1.575bn Continued growth investments in: Margin: 24% Ownership of strategic sites FCFF befor
Slide 7: Q&A
Q&A CONFIDENTIAL CONFIDENTIAL AND -PROPRIETARY AND PROPRIETARY - © Eurofins © Eurofins Scientific (Ireland) Scientific Ltd [2024]. (Ireland) All rights reserved. AnyLtd 2021. use of All rights this material reserved. without the specific Any use of permission ofanthis material authorized without the
Slide 8: Appendix
Appendix CONFIDENTIAL CONFIDENTIAL AND -PROPRIETARY AND PROPRIETARY - © Eurofins © Eurofins Scientific (Ireland) Scientific Ltd [2024]. (Ireland) All rights reserved. AnyLtd 2021. use of All rights this material reserved. without the specific Any use of permission ofanthis material authorized withou
Slide 9: Revenue by activity in Q1 2024
Revenue by activity in Q1 2024 Q1 2023: +6.6%1 Q2 2023: +7.5%1 Activities are defined as follows: ~10% • Life: • Food and Feed Testing • Agro Testing ~20% ~40% • Environment Testing • BioPharma: • BioPharma Services • Agrosciences • Genomics • Forensic Services • Diagnostic Services & Products: • Cl
Slide 10: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) APMs used in this presentation Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items (SDI) – include: • one-off costs from integration and reor